 Home > Active Ingredient News > Antitumor Therapy > Front Oncol: Efficacy of TACE combined with ICIs+TKIs in the treatment of unresectable hepatocellular carcinoma

Front Oncol: Efficacy of TACE combined with ICIs+TKIs in the treatment of unresectable hepatocellular carcinoma

 Last Update: 2022-01-23
 Source: Internet
 Author: User

Tags

tetanus immune globulin

1 8 channel

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Recently, a team from Soochow University published a study in the journal Frontiers in Oncology, mainly to explore the inability of transarterial chemoembolization (TACE) combined with immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) to treat patients.
Safety and efficacy of resected hepatocellular carcinoma (uHCC)
.

immunity

This study retrospectively analyzed patients with unresectable hepatocellular carcinoma (uHCC) who received TACE combined with ICIs and TKIs from August 2019 to July 2020
.

Treatment-related adverse events (AEs) were recorded

This study retrospectively analyzed patients with unresectable hepatocellular carcinoma (uHCC) who received TACE combined with ICIs and TKIs from August 2019 to July 2020

From August 1, 2019 to July 31, 2020, 31 uHCC patients were included

Twenty-nine (93%) patients experienced at least one adverse event (AE) during treatment, with an incidence greater than 10% including reactive capillary endothelial hyperplasia (RCCEP, n=15; 48.

Adverse reactions

Among the best treatment responses, 7 patients achieved complete remission (23%) and 13 patients achieved partial remission (41.
5%)
.

Therefore, the objective response rate (ORR) was 64.

Among the best treatment responses, 7 patients achieved complete remission (23%) and 13 patients achieved partial remission (41.

Efficacy assessment

Twenty patients achieved objective responses, with a median treatment-to-response time of 7 weeks (range, 4-30 weeks)
.

The duration of response was 17.

Twenty patients achieved objective responses, with a median treatment-to-response time of 7 weeks (range, 4-30 weeks)

TTP and PFS

In conclusion, the study shows that TACE combined with ICIs+TKIs has good curative effect and controllable toxicity in the treatment of unresectable hepatocellular carcinoma (uHCC)
.

Studies have shown that TACE combined with ICIs+TKIs has good efficacy and controllable toxicity in the treatment of unresectable hepatocellular carcinoma (uHCC)

Original source:

Yang F, Yang J, Xiang W, Zhong BY, Li WC, Shen J, Zhang S, Yin Y, Sun HP, Wang WS and Zhu XL (2022) Safety and Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.